The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2020 | Highlights in CLL at ASH 2020
Arnon Kater, MD, PhD, University of Amsterdam, Amsterdam, The Netherlands, shares his highlights from ASH 2020. Prof. Kater discusses updates from the CLL14 trial (NCT02242942) comparing obinutuzumab plus venetoclax with obinutuzumab plus chlorambucil in patients with chronic lymphocytic leukemia (CLL). He also outlines advances in chimeric antigen T-cell receptor (CAR-T) therapy and with the BTK inhibitor LOXO-305. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
Disclosures
Dr Arnon Kater, MD, PhD, has received research funding from BMS, Roche/Genentech, Johnson & Johnson and AbbVie; has received speakers fees from AbbVie; and is a member of advisory boards for Roche/Genentech, Johnson & Johnson and AbbVie.
